-
Mashup Score: 15NSCLC Clinical Case Simulations for Practicing Oncologists - 2 day(s) ago
Welcome to our interactive training module. Please select from below to
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
Tina Cascone, MD, PhD, discusses the CheckMate-77T trial of perioperative regimen of neoadjuvant nivolumab plus chemotherapy followed by surgery and adjuvant nivolumab for the treatment of patients with stage IIA to IIIB non-small cell lung cancer.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2
Investigators of the phase 3 ALINA trial report no unexpected safety findings with alectinib in ALK-positive non–small cell lung cancer.
Source: www.cancernetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
A series of phase 3 findings support the European approval of tislelizumab as a first-line and second-line treatment for non–small cell lung cancer.
Source: www.cancernetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Alectinib OK’d for NSCLC - 6 day(s) ago
Genentech’s alectinib (Alecensa) received FDA approval for adjuvant treatment of non–small cell lung cancer (NSCLC) in patients with ALK-positive disease. The decision was based on the phase III ALINA trial, in which 257 patients with stage IB to IIIA NSCLC received either alectinib or platinum-based chemotherapy following surgery (N Engl J Med 2024;390:1265–76). Researchers reported that median disease-free survival (DFS) among patients with stage II to IIIA disease who received the ALK inhibitor was not reached, whereas median DFS was 44.4 months among those who received chemotherapy. In the overall study population, median DFS was not reached with alectinib and was 41.3 months with chemotherapy.
Source: aacrjournals.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 6FDA Approves Alectinib for Early-Stage ALK+ NSCLC - 6 day(s) ago
The FDA has approved alectinib for the adjuvant treatment of patients with ALK-positive non-small cell lung cancer with tumors that are least 4 cm or node positive, as detected by an FDA-approved test.
Source: www.cancernetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
Aims To investigate the genomic discordances and heterogeneous mutational burden, PD-L1 expression and immune cell (IC) infiltrates of non-small cell lung cancer (NSCLC) metastasis. Methods Surgical samples from 41 cases of NSCLC with metastatic tumours (MTs) and paired primary tumours (PTs) were collected. PD-L1 expression and ICs were quantified using image-based immunohistochemistry profiling. Whole exome sequencing was employed to explore discrepancies in genomic characteristics, tumour mutational burden (TMB) and tumour neoantigen burden (TNB) in 28 cases. Results Non-synonymous mutations in MTs were slightly more than in PTs, with only 42.34% of mutations shared between paired PTs and MTs. The heterogeneity of TMB showed no significant difference (p=0.785) between MTs and PTs, while TNB significantly increased in MTs (p=0.013). MTs generally exhibited a higher density of PD-L1+ cells and a higher tumour proportion score with a lower density of IC infiltrates. Subgroup analysis co
Source: jcp.bmj.comCategories: General Medicine News, General HCPsTweet-
Exploring complexity #NSCLC metastasis 🧬🔍 Significant discordance in PD-L1 expression, immune cell infiltration, TMB, and TNB between primary tumors and metastases. Highlights need for personalized approaches in metastatic NSCLC treatment strategies🔬"https://t.co/sjcFjnRVQi https://t.co/Lh3reHlChR
-
-
Mashup Score: 6FDA Approves Alectinib for Early-Stage ALK+ NSCLC - 10 day(s) ago
The FDA has approved alectinib for the adjuvant treatment of patients with ALK-positive non-small cell lung cancer with tumors that are least 4 cm or node positive, as detected by an FDA-approved test.
Source: www.cancernetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 4
According to a subset analysis of the phase 3 MARIPOSA trial, dose interruptions during the course of amivantamab and lazertinib treatment were still effective in EGFR-mutant non-small cell lung cancer.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
The phase 1/2 WU-KONG1 findings support the breakthrough therapy designation for sunvozertinib for those with EGFR-mutated non–small cell lung cancer.
Source: www.cancernetwork.comCategories: General Medicine News, Onc News and JournalsTweet
🔬 Unlock precision medicine in #NSCLC with the premier Clinical Case Simulations from The Biomarker Consortium. Join Eric K. Singhi, MD from @MDAndersonNews as he delves into the significance of molecular testing. @esinghimd Dive in now: https://t.co/LKLF20eEC4 https://t.co/Ri55dG9P1j